Cystic Fibrosis (CF) Current Treatment Insights

Thelansis’s “Cystic Fibrosis (CF) Current Treatment Insights Report – 2025″ describes the current treatment and management in Cystic Fibrosis. The analysis includes various current approved and off-label therapies, their respective doses, durations, efficacy, and safety benchmarks. The use of treatments by a line of therapy, including their KOL-perceived advantages and disadvantages, is studied. In addition, an in-depth assessment of patient characteristics, diagnosis, comorbidities and their treatment, treatment switch, polypharmacy, compliance, and persistence is conducted.

Cystic Fibrosis (CF) Overview

Cystic Fibrosis (CF) is a serious, life-shortening autosomal recessive genetic disorder caused by mutations in the CFTR gene, resulting in a defective chloride and water channel that disrupts fluid transport across epithelial cells. This core defect leads to the formation of abnormally thick, sticky secretions that obstruct and damage multiple organs, most critically the lungs (causing chronic infection, inflammation, and progressive bronchiectasis) and the pancreas (leading to insufficiency and malabsorption). Clinical presentation often begins in infancy with a persistent cough, recurrent pulmonary issues, and poor growth, while an elevated sweat chloride test and genetic analysis typically confirm diagnosis. Treatment has been significantly advanced by CFTR modulators (like elexacaftor/tezacaftor/ivacaftor), which target the underlying protein malfunction in eligible patients, used alongside essential supportive care such as airway clearance, antibiotics, and enzyme replacement therapy, all of which are managed through lifelong, multidisciplinary care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician specialty(ies) involved in the diagnosis and treatment of patients:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Patient characteristics/patient segments
• Patient diagnosis criteria
• Patient shares for current therapies
• Line of therapy analysis
• Treatment sequencing
• Patient journey
• Compliance and persistency analysis
• Polypharmacy
• Factors impacting physician choice of treatments
• Drivers and barriers to prescribing key brands/treatments
• Physician-perceived advantages and disadvantages of current therapies
• Evolving treatment landscape
• KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)